Reviral Ltd - Revitalising antivirals

ReViral Drug Discovery for Respiratory Syncytial Virus (RSV)

ReViral is a UK-based biotechnology company with a portfolio of drugs to treat Respiratory Syncytial Virus (RSV) infection. RSV currently represents a major unmet medical need in children, the elderly and the immunocompromised.

Our most advanced programme, RV521, is a highly potent, orally-administered inhibitor of RSV fusion protein, and has demonstrated top-line safety and pharmacokinetic data in Phase 1 single and multiple ascending dose (SAD and MAD) trials. RV521 has successfully completed a Phase 2a proof-of-concept study in adult volunteers. RV521 will start clinical trials in patients in 2018.

RV521 best-in-class drug to treat RSV infections

RV521 is an orally available antiviral with excellent drug-like characteristics
Binds to the RSV fusion protein, blocking viral entry and preventing cell-to-cell spread
The compound demonstrates potent activity against multiple clinical strains of RSV

RSV Medical Need

RSV is the main cause of hospitalisation for children under the age of 5 and a major cause of hospitalisation for the elderly
Currently, there are no effective treatments or vaccines available against RSV
There is a clear unmet need for a safe and effective treatment with a simple route of administration

Meet the team...